Broadfin Capital Opens a Stake in Celsus, Another Biotech Company Today

Broadfin Capital, Celsus: Broadfin Capital, managed by Kevin Kotler, just disclosed a position in Celsus Therapeutics (OTCQB: CLSXY).

Keep Reading →